Ian C. Locke

1.6k total citations · 1 hit paper
41 papers, 1.3k citations indexed

About

Ian C. Locke is a scholar working on Biomaterials, Molecular Biology and Rehabilitation. According to data from OpenAlex, Ian C. Locke has authored 41 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Biomaterials, 9 papers in Molecular Biology and 7 papers in Rehabilitation. Recurrent topics in Ian C. Locke's work include biodegradable polymer synthesis and properties (10 papers), Stress Responses and Cortisol (7 papers) and Electrospun Nanofibers in Biomedical Applications (6 papers). Ian C. Locke is often cited by papers focused on biodegradable polymer synthesis and properties (10 papers), Stress Responses and Cortisol (7 papers) and Electrospun Nanofibers in Biomedical Applications (6 papers). Ian C. Locke collaborates with scholars based in United Kingdom, Germany and South Korea. Ian C. Locke's co-authors include Chantell S. Evans, Stephen J. Getting, Zhenqiang Yao, Anjali Prashar, Tajalli Keshavarz, Ipsita Roy, Aldo R. Boccaccini, Jonathan C. Knowles, Thierry Tron and Godfrey Kyazze and has published in prestigious journals such as Nucleic Acids Research, Scientific Reports and Carbohydrate Polymers.

In The Last Decade

Ian C. Locke

41 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regulation of TNF-Induced Osteoclast Differentiation

2021 186 citations Stephen J. Getting, Ian C. Locke et al. profile →

Peers

Countries citing papers authored by Ian C. Locke

Since Specialization

Citations

This map shows the geographic impact of Ian C. Locke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian C. Locke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian C. Locke more than expected).

Fields of papers citing papers by Ian C. Locke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian C. Locke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian C. Locke. The network helps show where Ian C. Locke may publish in the future.

Co-authorship network of co-authors of Ian C. Locke

This figure shows the co-authorship network connecting the top 25 collaborators of Ian C. Locke. A scholar is included among the top collaborators of Ian C. Locke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian C. Locke. Ian C. Locke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Novel anti-inflammatory and chondroprotective effects of the human melanocortin MC1 receptor agonist BMS-470539 dihydrochloride and human melanocortin MC3 receptor agonist PG-990 on lipopolysaccharide activated chondrocytes 2020 ·European Journal of Pharmacology ·(unknown), Ian C. Locke, (unknown), (unknown), Francesco Merlino, C. De Pascale, Paolo Grieco, Stephen J. Getting	13
2	Populated collagen hydrogel and polyhydroxyalkanoate composites: novel matrices for cartilage repair and regeneration? 2019 ·Osteoarthritis and Cartilage ·C. De Pascale, Elena Marcello, Stephen J. Getting, Ipsita Roy, Ian C. Locke	9
3	Chondroprotection by urocortin involves blockade of the mechanosensitive ion channel Piezo1 2017 ·Scientific Reports ·Kevin M. Lawrence, R.C. Jones, Thomas Jackson, (unknown), (unknown), Bożena Bruhn‐Olszewska, Tim Board, Ian C. Locke, Stephen M. Richardson, Paul A. Townsend	43
4	Development of bio-composites with novel characteristics: Evaluation of phenol-induced antibacterial, biocompatible and biodegradable behaviours 2015 ·Carbohydrate Polymers ·Hafiz M.N. Iqbal, Godfrey Kyazze, Ian C. Locke, Thierry Tron, Tajalli Keshavarz	29
5	Poly(3-hydroxybutyrate)-ethyl cellulose based bio-composites with novel characteristics for infection free wound healing application 2015 ·International Journal of Biological Macromolecules ·Hafiz M.N. Iqbal, Godfrey Kyazze, Ian C. Locke, Thierry Tron, Tajalli Keshavarz	27
6	Melanocortin peptides protect chondrocytes from mechanically induced cartilage injury 2014 ·Biochemical Pharmacology ·(unknown), (unknown), Paolo Grieco, G. Paul Curley, Ian C. Locke, Stephen J. Getting	12
7	Urocortin – From Parkinson's disease to the skeleton 2014 ·The International Journal of Biochemistry & Cell Biology ·Kevin M. Lawrence, (unknown), Daniel Jamieson, Adam Stevens, G Owens, Berna S. Sayan, Ian C. Locke, Paul A. Townsend	6
8	Urocortin protects chondrocytes from NO-induced apoptosis: a future therapy for osteoarthritis? 2013 ·Cell Death and Disease ·(unknown), (unknown), Stephen J. Getting, (unknown), Richard A. Knight, H.S. Chowdrey, Paul A. Townsend, Kevin M. Lawrence, Ian C. Locke	26
9	Chondroprotective and anti‐inflammatory role of melanocortin peptides in TNF‐α activated human C‐20/A4 chondrocytes 2012 ·British Journal of Pharmacology ·(unknown), (unknown), Paolo Grieco, G. Paul Curley, Ian C. Locke, Stephen J. Getting	31
10	Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channel 2011 ·Journal of Endocrinology ·(unknown), K. Fuller, (unknown), Anthony P. Albert, Grisha Pirianov, James A. McCormick, Ian C. Locke, Timothy Chambers, Kevin M. Lawrence	12
11	Melanocortin peptides modulate pro-inflammatory mediator release from TNF-a stimulated C-20/A4 cells 2009 ·WestminsterResearch (University of Westminster) ·(unknown), (unknown), Ian C. Locke, Stephen J. Getting	1
12	The corticotrophin‐releasing factor‐like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease 2007 ·European Journal of Neuroscience ·Amjad Abuirmeileh, Rebecca Lever, Ann E. Kingsbury, Andrew J. Lees, Ian C. Locke, Richard A. Knight, Hardial S. Chowdrey, Christopher S. Biggs, Peter S. Whitton	33
13	Interactions between cell surface protein disulphide isomerase and S-nitrosoglutathione during nitric oxide delivery 2006 ·Nitric Oxide ·Chirag Shah, Sarah E. Bell, Ian C. Locke, H.S. Chowdrey, M.P. Gordge	32
14	Cytotoxicity of clove (Syzygium aromaticum) oil and its major components to human skin cells 2006 ·Cell Proliferation ·(unknown), Ian C. Locke, Chantell S. Evans	204
15	Interactions between cell surface protein disulphide isomerase and S-nitrosoglutathione during nitric oxide delivery into MEG-01 megakaryocytes 2005 ·WestminsterResearch (University of Westminster) ·Chirag Shah, (unknown), Ian C. Locke, Hardial S. Chowdrey, (unknown)	1
16	Evidence for a neuroprotective role of the CRH-like peptide, urocortin, in the 6-hydroxydopamine treated rat 2005 ·WestminsterResearch (University of Westminster) ·C.S. Biggs, Ian C. Locke, R A Knight, H.S. Chowdrey, Peter S. Whitton	1
17	Cytotoxicity of lavender oil and its major components to human skin cells 2004 ·Cell Proliferation ·Anjali Prashar, Ian C. Locke, Chantell S. Evans	180
18	A comparison of the characteristics of circulating anti-myeloperoxidase autoantibodies in vasculitis with those in non-vasculitic conditions 1999 ·Clinical & Experimental Immunology ·Ian C. Locke, Brian Leaker, Geraldine Cambridge	22
19	Adjacent proline residues in the inhibitory domain of the Oct-2 transcription factor play distinct functional roles 1998 ·Nucleic Acids Research ·(unknown), (unknown), Ian C. Locke, Sally J. Dawson, D.S. Latchman	6
20	An automated method for the determination of deoxyribonuclease activity as exemplified by fractionation of the components of the medicament Varidase^® 1993 ·Journal of Analytical Methods in Chemistry ·Ian C. Locke, (unknown), (unknown), Brian Carpenter	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact